414 related articles for article (PubMed ID: 29741773)
1. Phase 2 trial of neoadjuvant chemotherapy and transoral endoscopic surgery with risk-adapted adjuvant therapy for squamous cell carcinoma of the head and neck.
Weiss JM; Grilley-Olson JE; Deal AM; Zevallos JP; Chera BS; Paul J; Knowles MF; Usenko D; Weissler MC; Patel S; Hayes DN; Hackman T
Cancer; 2018 Jul; 124(14):2986-2992. PubMed ID: 29741773
[TBL] [Abstract][Full Text] [Related]
2. Induction chemotherapy with carboplatin, nab-paclitaxel and cetuximab for at least N2b nodal status or surgically unresectable squamous cell carcinoma of the head and neck.
Weiss J; Gilbert J; Deal AM; Weissler M; Hilliard C; Chera B; Murphy B; Hackman T; Liao JJ; Grilley Olson J; Hayes DN
Oral Oncol; 2018 Sep; 84():46-51. PubMed ID: 30115475
[TBL] [Abstract][Full Text] [Related]
3. A Phase II Study of Genexol-PM and Cisplatin as Induction Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma.
Keam B; Lee KW; Lee SH; Kim JS; Kim JH; Wu HG; Eom KY; Kim S; Ahn SH; Chung EJ; Kwon SK; Jeong WJ; Jung YH; Kim JW; Heo DS
Oncologist; 2019 Jun; 24(6):751-e231. PubMed ID: 30796155
[TBL] [Abstract][Full Text] [Related]
4. Preoperative cisplatin and accelerated hyperfractionated radiation induces high tumor response and control rates in patients with advanced head and neck cancer.
Wanebo HJ; Glicksman AS; Landman C; Slotman G; Doolittle C; Clark J; Koness RJ
Am J Surg; 1995 Nov; 170(5):512-6. PubMed ID: 7485745
[TBL] [Abstract][Full Text] [Related]
5. Novel induction therapy transoral surgery treatment paradigm with risk-adapted adjuvant therapy for squamous cell carcinoma of the head and neck - Mature clinical and functional outcomes.
Hackman TG; Patel SN; Deal AM; Neil Hayes D; Chera BS; Paul J; Knowles M; Usenko D; Grilley-Olson JE; Weissler MC; Weiss J
Oral Oncol; 2020 Nov; 110():104957. PubMed ID: 32823258
[TBL] [Abstract][Full Text] [Related]
6. Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10-year update and subset analysis.
Iyer NG; Tan DS; Tan VK; Wang W; Hwang J; Tan NC; Sivanandan R; Tan HK; Lim WT; Ang MK; Wee J; Soo KC; Tan EH
Cancer; 2015 May; 121(10):1599-607. PubMed ID: 25639864
[TBL] [Abstract][Full Text] [Related]
7. Treatment of squamous cell carcinoma of external auditory canal: A tertiary cancer centre experience.
Gandhi AK; Roy S; Biswas A; Raza MW; Saxena T; Bhasker S; Sharma A; Thakar A; Mohanti BK
Auris Nasus Larynx; 2016 Feb; 43(1):45-9. PubMed ID: 26165629
[TBL] [Abstract][Full Text] [Related]
8. Planned post-chemoradiation neck dissection: significance of radiation dose.
Stenson KM; Huo D; Blair E; Cohen EE; Argiris A; Haraf DJ; Vokes EE
Laryngoscope; 2006 Jan; 116(1):33-6. PubMed ID: 16481805
[TBL] [Abstract][Full Text] [Related]
9. The addition of chemotherapy to adjuvant radiation is associated with inferior survival outcomes in intermediate-risk HPV-negative HNSCC.
Tasoulas J; Lenze NR; Farquhar D; P Schrank T; Shen C; Shazib MA; Singer B; Patel S; Grilley Olson JE; Hayes DN; Gulley ML; Chera BS; Hackman T; Olshan AF; Weiss J; Sheth S
Cancer Med; 2021 May; 10(10):3231-3239. PubMed ID: 33934525
[TBL] [Abstract][Full Text] [Related]
10. Phase I and initial phase II results from a trial investigating weekly docetaxel and carboplatin given neoadjuvantly and then concurrently with concomitant boost radiotherapy for locally advanced squamous cell carcinoma of the head and neck.
Schwartz DL; Montgomery RB; Yueh B; Donahue M; Anzai Y; Canby R; Buelna R; Anderson L; Boyd C; Hutson J; Keegan K
Cancer; 2005 Jun; 103(12):2534-43. PubMed ID: 15856475
[TBL] [Abstract][Full Text] [Related]
11. Phase II feasibility trial of adjuvant chemoradiotherapy with 3-weekly cisplatin for Japanese patients with post-operative high-risk squamous cell carcinoma of the head and neck.
Kiyota N; Tahara M; Okano S; Kawashima M; Matsuura K; Onozawa Y; Nibu K; Hayashi R; Yoshimura K; Ohtsu A
Jpn J Clin Oncol; 2012 Oct; 42(10):927-33. PubMed ID: 22923484
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant chemoradiotherapy with concurrent cisplatin/5-fluorouracil is associated with increased pathologic complete response and improved survival compared to carboplatin/paclitaxel in patients with locally advanced esophageal cancer.
Haisley KR; Hart KD; Nabavizadeh N; Bensch KG; Vaccaro GM; Thomas CR; Schipper PH; Hunter JG; Dolan JP
Dis Esophagus; 2017 Jul; 30(7):1-7. PubMed ID: 28475724
[TBL] [Abstract][Full Text] [Related]
13. Postoperative concurrent chemotherapy and radiotherapy for high-risk cutaneous squamous cell carcinoma of the head and neck.
Tanvetyanon T; Padhya T; McCaffrey J; Kish JA; Deconti RC; Trotti A; Rao NG
Head Neck; 2015 Jun; 37(6):840-5. PubMed ID: 24623654
[TBL] [Abstract][Full Text] [Related]
14. Single-cycle induction chemotherapy before chemoradiotherapy or surgery in functionally inoperable head and neck squamous cell carcinoma: 10-year results.
Breheret M; Lubgan D; Haderlein M; Hecht M; Traxdorf M; Schmidt D; Müller S; Kitzsteiner C; Kuwert T; Iro H; Fietkau R; Semrau S
Eur Arch Otorhinolaryngol; 2020 Jan; 277(1):245-254. PubMed ID: 31583430
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of docetaxel, cisplatin, and concurrent radiation followed by platinum-based adjuvant chemotherapy for technically unresectable, locally advanced head and neck squamous cell carcinoma.
Nakahara S; Takenaka Y; Ogawa K; Nishiike S; Yamamoto Y; Seo Y; Isohashi F; Suzuki O; Yoshioka Y; Sumida I; Yoshii T; Tomiyama Y; Inohara H
Int J Clin Oncol; 2016 Dec; 21(6):1030-1037. PubMed ID: 27306220
[TBL] [Abstract][Full Text] [Related]
16. Phase III study of nivolumab alone or combined with ipilimumab as immunotherapy versus standard of care in resectable head and neck squamous cell carcinoma.
Zech HB; Moeckelmann N; Boettcher A; Muenscher A; Binder M; Vettorazzi E; Bokemeyer C; Schafhausen P; Betz CS; Busch CJ
Future Oncol; 2020 Dec; 16(36):3035-3043. PubMed ID: 32902312
[TBL] [Abstract][Full Text] [Related]
17. Comparative effectiveness trial of transoral head and neck surgery followed by adjuvant radio(chemo)therapy versus primary radiochemotherapy for oropharyngeal cancer (TopROC).
Bußmann L; Laban S; Wittekindt C; Stromberger C; Tribius S; Möckelmann N; Böttcher A; Betz CS; Klussmann JP; Budach V; Muenscher A; Busch CJ
BMC Cancer; 2020 Jul; 20(1):701. PubMed ID: 32727416
[TBL] [Abstract][Full Text] [Related]
18. Surgical resection is necessary to maximize tumor control in function-preserving, aggressive chemoradiation protocols for advanced squamous cancer of the head and neck (stage III and IV).
Wanebo H; Chougule P; Ready N; Safran H; Ackerley W; Koness RJ; McRae R; Nigri P; Leone L; Radie-Keane K; Reiss P; Kennedy T
Ann Surg Oncol; 2001 Sep; 8(8):644-50. PubMed ID: 11569779
[TBL] [Abstract][Full Text] [Related]
19. Early postoperative paclitaxel followed by concurrent paclitaxel and cisplatin with radiation therapy for patients with resected high-risk head and neck squamous cell carcinoma: report of the phase II trial RTOG 0024.
Rosenthal DI; Harris J; Forastiere AA; Weber RS; Ridge JA; Myers JN; Garden AS; Kuettel MR; Sidhu K; Schultz CJ; Trotti A; Ang KK
J Clin Oncol; 2009 Oct; 27(28):4727-32. PubMed ID: 19720915
[TBL] [Abstract][Full Text] [Related]
20. Phase 2 study of docetaxel, cisplatin, and concurrent radiation for technically resectable stage III-IV squamous cell carcinoma of the head and neck.
Inohara H; Takenaka Y; Yoshii T; Nakahara S; Yamamoto Y; Tomiyama Y; Seo Y; Isohashi F; Suzuki O; Yoshioka Y; Sumida I; Ogawa K
Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):934-41. PubMed ID: 25832686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
